A Deep Dive Into IL-17 Inhibition and Bimekizumab for Psoriasis: Straight Talk with Dr Andy Blauvelt
In this episode of Derms and Conditions, Andy Blauvelt, MD, joins James Q. Del Rosso, DO, to discuss IL-17 inhibition, with a focus on bimekizumab as a treatment for psoriasis. Bimekizumab is unique for inhibiting both IL-17A and IL-17F, demonstrating higher efficacy and a favorable safety profile. Dr Blauvelt highlights the drug's mechanism of action and covers its approval process, global use, and notable data. He emphasizes its efficacy in achieving Psoriasis Area Severity Index 100 (PASI 100) clearance.
The pair discusses bimekizumab’s dosing schedule, with an induction dosing period of…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.